Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shmuel Klang is active.

Publication


Featured researches published by Shmuel Klang.


The American Journal of Gastroenterology | 2009

Sensitivity, but Not Specificity, of a Quantitative Immunochemical Fecal Occult Blood Test for Neoplasia Is Slightly Increased by the Use of Low-Dose Aspirin, NSAIDS, and Anticoagulants

Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Nicky Lieberman; Shmuel Klang; Yaron Niv

OBJECTIVES:We evaluated the effect of the use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), and anticoagulants on the performance of immunochemical fecal occult blood test (I-FOBT).METHODS:A prospective, cross-sectional study of 1,221 ambulatory patients having total colonoscopy after preparing three I-FOBTs. Information regarding the use of medications was collected from the health medical organization (HMO) database. I-FOBT was analyzed with the OC-MICRO instrument using both ≥75 and 100 ngHb/ml of buffer thresholds to determine positivity.RESULTS:Colorectal cancer (CRC) was found in 17 and advanced adenomatous polyp (AAP) in 97 patients. A total of 212 patients were using aspirin/NSAIDS at the time of I-FOBT testing. Qualitative analysis for the detection of AAP/CRC reveals a trend for an increased sensitivity with aspirin/NSAIDS use. At the threshold 75 ng/ml for positivity, the sensitivity for the detection of AAP/CRC was 66.7% for aspirin/NSAIDS use vs. 51.2% for nondrug takers (P=0.20), and at the threshold of 100 ng/ml, the sensitivity was 66.7 vs. 46.5% (P=0.09). The specificity, however, was not affected by the use of aspirin/NSAIDS. At the threshold of 75 ng/ml for positivity, the specificity for the detection of AAP/CRC was 89.5% for aspirin/NSAIDS use vs. 91.2% for nondrug takers (P=0.47), and at the threshold of 100 ng/ml, the specificity was 92.17 vs. 93.0% (P=0.69). A total of 33 patients were using antithrombotics/coagulants at the time of I-FOBT testing. This group was small; however, it appears that their use was also associated with a trend for increased sensitivity and no change in specificity.CONCLUSIONS:The use of aspirin/NSAIDS and anticoagulants was associated with a trend for increased sensitivity with no change in specificity for the detection of AAP/CRC. This study suggests that there is no need to stop these agents before I-FOBT testing.


Annals of Pharmacotherapy | 2008

Antipsychotics and Diabetes: An Age-Related Association

Ariel Hammerman; Jacob Dreiher; Shmuel Klang; Hanan Munitz; Arnon D. Cohen; Margalit Goldfracht

Background Previous studies have reported an association between antipsychotic medications and diabetes. Objective To explore the association between antipsychotic medications and diabetes in patients of different ages. Methods A retrospective analysis of a large health maintenance organizations drug claim database (3.7 million members) was performed. All patients treated with antipsychotic drugs during 1998–2004 were identified. Patients with diabetes were defined by a record of antidiabetic drug uso during 2004. The prevalence of diabetes in different age groups treated with antipsychotics was compared with the prevalence of diabetes among enrollees in the same age groups not treated with antipsychotics. Results: Among 82,754 patients treated with antipsychotics, the association between diabetes and consumption of antipsychotics was strongest in the younger age groups and decreased with increasing age: for patients aged 0–24 years, OR 8.9 (95% CI 7.0 to 11.3); 25–44 years, OR 4.2 (95% CI 3,8 to 4.5); 45–54 years, OR 1.9 (95% CI 1.8 to 2.1); 55–64 years, OR 1.3 (95% CI 1.2 to 1.4); and 65 years or older, OR 0.93 (95% CI 0.9 to 1.0). However, the risk associated with atypical antipsychotics was lower than the risk associated with typical antipsychotics, with ORs ranging from 0.7 in patients 0–24 years old to 0.3 in those 65 years or older. Conclusions: Antipsychotic drug use was associated with diabetes mellitus. This association was stronger in younger patients. In older adults, the difference was much smaller and, in some cases, there was no association. A lowor risk was associated with atypical agents, as compared with typical antipsychotics. Clinicians should bo aware that young adults treated with antipsychotics are at increased risk for diabetes.


Value in Health | 2010

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.

Shmuel Klang; Ariel Hammerman; Nicky Liebermann; Noa Efrat; Julie Doberne; John Hornberger


Breast Cancer Research and Treatment | 2013

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients

Salomon M. Stemmer; Shmuel Klang; Noa Ben-Baruch; David B. Geffen; Mariana Steiner; Lior Soussan-Gutman; Shahar Merling; Christer Svedman; Shulamith Rizel; Nicky Lieberman


Journal of Clinical Oncology | 2010

The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.

Shmuel Klang; Nicky Liebermann; Shulamith Rizel; Noa Ben-Baruch; Shahar Merling; Lior Soussan-Gutman; R. Bugarini; C. Chao; Steven Shak


Value in Health | 2006

PCN57 TRASTUZUMAB USE FOR METASTATIC BREAST CANCER–IS “MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE PARAMETER FOR BUDGET IMPACT ANALYSIS?

Ariel Hammerman; Shmuel Klang; Nicky Liebermann


Journal of Clinical Oncology | 2017

Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).

Salomon M. Stemmer; Mariana Steiner; Shulamith Rizel; Noa Ben Baruch; Lior Soussan-Gutman; Avital Bareket-Samish; Bella Nisenbaum; Kevin Isaacs; Georgeta Fried; Ora Rosengarten; Tamar Peretz; Christer Svedman; Debbie McCullough; Shmuel Klang; Jamal Zidan; Larisa Ryvo; Bella Kaufman; Steven Shak; Nicky Liebermann; David B. Geffen


Journal of Clinical Oncology | 2017

Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.

Salomon M. Stemmer; Mariana Steiner; Shulamith Rizel; Noa Ben Baruch; David B. Geffen; Lior Soussan-Gutman; Avital Bareket-Samish; Bella Nisenbaum; Kevin Isaacs; Georgeta Fried; Ora Rosengarten; Beatrice Uziely; Christer Svedman; Debbie McCullough; Shmuel Klang; Ella Evron; Natalya Karminsky; Hadassah Goldberg; Steven Shak; Nicky Liebermann


Journal of Clinical Oncology | 2017

Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience.

Baruch Brenner; Ravit Geva; Alexander Beny; Ygael Dror; Mariana Steiner; Ayala Hubert; Efraim Idelevich; Alexander Gluzman; Ofer Purim; Einat Shacham-Shmueli; Katerina Shulman; Lior Soussan-Gutman; Shmuel Klang; Shahar Merling; Nicky Liebermann


Value in Health | 2009

PCN20 REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS— A COMPARATIVE ANALYSIS

Ariel Hammerman; Shmuel Klang; Nicky Liebermann

Collaboration


Dive into the Shmuel Klang's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David B. Geffen

Ben-Gurion University of the Negev

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Georgeta Fried

Rambam Health Care Campus

View shared research outputs
Researchain Logo
Decentralizing Knowledge